Page 74 - 51 the significance--29.2_opt

References
1. Creutzfeldt W, Ebert R. New developments in the incretin concept. Diabetologia
1985;28(8):565-73.
2. Drucker DJ. The biology of incretin hormones. Cell metabolism 2006;3(3):153-65.
3. Meier JJ, Gethmann A, Nauck MA, Gotze O, Schmitz F, Deacon CF, et al. The
glucagon-like peptide-1 metabolite GLP-1-(9-36) amide reduces postprandial
glycemia independently of gastric emptying and insulin secretion in humans.
American journal of physiology. Endocrinology and metabolism 2006;290(6):E1118-23.
4. Drucker DJ. Glucagon-like peptides: regulators of cell proliferation, differentiation,
and apoptosis. Mol Endocrinol 2003;17(2):161-71.
5. Farilla L, Hui H, Bertolotto C, Kang E, Bulotta A, Di Mario U, et al. Glucagon-like
peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats.
Endocrinology 2002;143(11):4397-408.
6. Knop FK, Vilsboll T, Hojberg PV, Larsen S, Madsbad S, Volund A, et al. Reduced
incretin effect in type 2 diabetes: cause or consequence of the diabetic state?
Diabetes 2007;56(8):1951-9.
7. Toft-Nielsen MB, Damholt MB, Madsbad S, Hilsted LM, Hughes TE, Michelsen BK, et al.
Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic
patients. The Journal of clinical endocrinology and metabolism 2001;86(8):3717-23.
8. Vilsboll T, Krarup T, Deacon CF, Madsbad S, Holst JJ. Reduced postprandial concen-
trations of intact biologically active glucagon-like peptide 1 in type 2 diabetic
patients. Diabetes 2001;50(3):609-13.
9. Nauck MA, Vardarli I, Deacon CF, Holst JJ, Meier JJ. Secretion of glucagon-like
peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down? Diabetologia 2011;
54(1):10-8.
10. Kjems LL, Holst JJ, Volund A, Madsbad S. The influence of GLP-1 on glucose-stimu-
lated insulin secretion: effects on beta-cell sensitivity in type 2 and nondiabetic
subjects. Diabetes 2003;52(2):380-6.
11. Vilsboll T, Krarup T, Madsbad S, Holst JJ. Defective amplification of the late phase
insulin response to glucose by GIP in obese Type II diabetic patients. Diabetologia
2002;45(8):1111-9.
12. Nauck MA, Heimesaat MM, Orskov C, Holst JJ, Ebert R, Creutzfeldt W. Preserved
incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human
gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. The Journal
of clinical investigation 1993;91(1):301-7.
13. Knop FK, Vilsboll T, Madsbad S, Krarup T, Holst JJ. Lack of suppression of glucagon
during OGTT but not during isoglycemic IVGTT in patients with type 2 diabetes.
Diabetes 2006;55 (Suppl. 1).
14. Meier JJ, Deacon CF, Schmidt WE, Holst JJ, Nauck MA. Suppression of glucagon
secretion is lower after oral glucose administration than during intravenous glucose
administration in human subjects. Diabetologia 2007;50(4):806-13.
15. Chen X. Biochemical properties of recombinant prolyl dipeptidases DPP-IV and
DPP8. Adv Exp Med Biol 2006;575:27-32.
16. Deacon CF, Nauck MA, Toft-Nielsen M, Pridal L, Willms B, Holst JJ. Both subcutaneously
and intravenously administered glucagon-like peptide I are rapidly degraded
from the NH2-terminus in type II diabetic patients and in healthy subjects. Diabetes
1995;44(9):1126-31.
17. Deacon CF, Nauck MA, Meier J, Hucking K, Holst JJ. Degradation of endogenous
and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic
subjects as revealed using a new assay for the intact peptide. The Journal of clinical
endocrinology and metabolism 2000;85(10):3575-81.
18. Pratley RE, Salsali A. Inhibition of DPP-4: a new therapeutic approach for the treat-
ment of type 2 diabetes. Current medical research and opinion 2007;23(4):919-31.
19. Bristol-Myers Squibb Pharmaceuticals Ltd and AstraZeneca EEIG. Onglyza® Summary
of Product Characteristics. June, 2009.
20. Merck Sharpe & Dohme Ltd. Januvia® Summary of Product Characteristics. 2009.
21. Novartis Europharm Ltd. Galvus® Summary of Product Characteristics. 2009.
22. Levetan C. Oral antidiabetic agents in type 2 diabetes. Current medical research
and opinion 2007;23(4):945-52.
23. Hanefeld M, Herman GA, Wu M, Mickel C, Sanchez M, Stein PP. Once-daily sitagliptin,
a dipeptidyl peptidase-4 inhibitor, for the treatment of patients with type 2 diabetes.
Current medical research and opinion 2007;23(6):1329-39.

74